Other substances

mAb2

An anti-Spike receptor binding motif (SARS-CoV-2) antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

mAb2 is a monoclonal antibody selected for its affinity for receptor-binding motif (RBM) of SARS-CoV-2 Spike protein. It inhibited RBM-ACE2 interaction and decreased GM‐CSF secretion by human peripheral blood mononuclear cells, murine macrophage-like cells, and hACE2-expressing mice stimulated by RBM in vitro (Qiang et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Monoclonal antibodies capable of binding SARS‐CoV‐2 spike protein receptor‐binding motif specifically prevent GM‐CSF induction
Spike protein ACE2 Animal model In vitro Antibody 		RAW 264.7 cells; human peripheral blood mononuclear cells; K18‐hACE2 mice 3.76

The antibody displayed dose-dependent binding of receptor binding motif (RBM) of SARS-CoV-2 Spike protein in vitro (KD of 62.8 nM). It competitively inhibited the RBM-ACE2 interaction and reduced RBM-stimulated secretion of GM-CSF by primary human peripheral blood mononuclear cells, murine macrophage-like cells, and in hACE2 mice. This activity was hypothesized to prevent cytokine storm development.

 Mar/24/2021

AI-suggested references

Link Publication date
Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
Sep/16/2021
Export (.csv)